|
PROXIMAGEN NEUROSCIENCE PLC
(Proximagen or the Company)
BOARD APPOINTMENT OF FINANCE DIRECTOR
London, UK, 27 February 2006 - Proximagen Neuroscience plc (AIM: PRX), the
specialty drug discovery and development company focused on neurodegenerative
diseases, is pleased to announce that James Hunter, formerly Proximagen's
Financial Controller, has joined the Board as Finance Director.
James joined the Company as Financial Controller in January 2005. Prior to
joining Proximagen, James spent six years working in the corporate finance team
at Ernst & Young where he was focused primarily on restructuring and M&A. James
joined Ernst & Young after completing an MBA at the Cranfield School of
Management.
The directorships held by James Douglas Hunter (aged 38) now and over the five
years preceding the date of appointment are as follows:
Current: None
Previous: Freedom Ventures Limited
As at the date of this announcement, James Hunter holds options over 210,267
ordinary shares of 1p each in the capital of the Company, of which 150,267
(representing 0.75% of the issued share capital of the Company) were granted on
appointment.
Commenting on the appointment, Kenneth Mulvany, Chief Executive Officer of
Proximagen, said:
"I am delighted to announce that James has joined Proximagen's
Board. He has made a significant contribution to the Company to date, including
the IPO process last year, and subsequently to the strategy and growth of the
business. I am confident that his appointment to the Board will strengthen the
Company's position through its next stage of growth."
Proximagen confirms that, save for the above, there are no other matters under
paragraph (g) of Schedule 2 of the AIM rules to be announced.
For more information please contact:
Proximagen Neuroscience plc (www.proximagen.com)
020 7848 6011
Kenneth Mulvany, Chief Executive Officer
James Hunter, Financial Director
Buchanan Communications
020 7466 5000
Tim Anderson / Mark Court / Mary-Jane Johnson
About Proximagen
Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease.
The Company was founded by Professor Peter Jenner in conjunction with King's College in November 2003 to draw upon over 25 years of pre-eminent neurodegenerative research.
Proximagen joined the AIM market of the London Stock Exchange in March 2005.
| 
